<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39348200</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0929</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Toxicological sciences : an official journal of the Society of Toxicology</Title><ISOAbbreviation>Toxicol Sci</ISOAbbreviation></Journal><ArticleTitle>Schisandrin C prevents Regorafenib-Induced cardiotoxicity by recovering EPHA2 expression in cardiomyocytes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">kfae127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/toxsci/kfae127</ELocationID><Abstract><AbstractText>Regorafenib, an oral multikinase inhibitor of angiogenic, stromal, and oncogenic receptor tyrosine kinases, has been approved for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma by the US Food and Drug Administration and European Medicines Agency. However, regorafenib-induced cardiotoxicity increases the risk of mortality. Despite reports that regorafenib can cause mitochondrial dysfunction in cardiomyocytes, the molecular mechanism of regorafenib-induced cardiotoxicity is much less known and there is an urgent need for intervention strategies. Here, we treated mice with vehicle or 200 mg/kg regorafenib daily for 42 days by gavage or treated cardiomyocyte lines with 8, 16 or 32 μM regorafenib, and we found that regorafenib could cause apoptosis, mitochondrial injury and DNA damage in cardiomyocytes. Mechanistically, regorafenib can reduce the expression of EPHA2, which inhibits AKT signaling, leading to cardiomyocyte apoptosis and cardiotoxicity. In addition, we showed that recovering EPHA2 expression via plasmid-induced overexpression of EPHA2 or schisandrin C, a natural product, could prevent regorafenib-induced cardiotoxicity. These findings demonstrated that regorafenib causes cardiomyocyte apoptosis and cardiac injury by reducing the expression of EPHA2 and schisandrin C could prevent regorafenib-induced cardiotoxicity by recovering EPHA2 expression, which provides a potential management strategy for regorafenib-induced cardiotoxicity and will benefit the safe application of regorafenib in clinic.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Emergency Department, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, 310016, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Taicheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liyu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, 310009, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wentong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Huangxi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xueqin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Affiliated Hangzhou First People's Hospital, Xihu University School of Medicine, Zhejiang, 310006, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaochun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Peihua</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, 310009, P.R.China Hangzhou.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Zhejiang, 310018, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology &amp; Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Hangzhou City University, Zhejiang, 310015, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhifei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qiaojun</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center for Drug Safety Evaluation and Research of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, 310058, P.R.China Hangzhou.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, 310009, P.R.China Hangzhou.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Zhejiang, 310018, P.R.China Hangzhou.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Toxicol Sci</MedlineTA><NlmUniqueID>9805461</NlmUniqueID><ISSNLinking>1096-0929</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Cardiotoxicity</Keyword><Keyword MajorTopicYN="N">DNA damage</Keyword><Keyword MajorTopicYN="N">EPHA2</Keyword><Keyword MajorTopicYN="N">Regorafenib</Keyword><Keyword MajorTopicYN="N">Schisandrin C</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39348200</ArticleId><ArticleId IdType="doi">10.1093/toxsci/kfae127</ArticleId><ArticleId IdType="pii">7796570</ArticleId></ArticleIdList></PubmedData></PubmedArticle>